SEC filing record
Primary Source · SEC.gov

ZIMMER BIOMET HOLDINGS, INC.

2023 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Raised

$216M

Investors

157

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

ZIMMER BIOMET HOLDINGS, INC. is a Delaware corporation that filed a Form D with the SEC on February 15, 2023 in the Other Health Care industry group. The offering claims Rule 506(b) and covers equity. ZIMMER BIOMET HOLDINGS, INC. reported $216,086,331 sold from 157 investors of a $216,086,331 total offering as of the Form D filed February 15, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 345 East Main Street, Warsaw, IN 46580.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001136869
Entity NameZIMMER BIOMET HOLDINGS, INC.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address345 East Main Street, Warsaw, IN 46580
Phone(574) 267-6131
Former NamesZIMMER HOLDINGS INC (until June 8, 2015)
Industry / Fund TypeOther Health Care
Securities TypeEquity
First Sale DateFebruary 6, 2023
Filing DateFebruary 15, 2023
Accession Number0001209191-23-009703
Total Offering Amount$216,086,331
Total Amount Sold$216,086,331
Amount Remaining$0
Total Investors157
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeOver $100,000,000
State (Issuer Address)IN
Amendment CountOriginal filing only

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

0

none on file

Critical / warning

0 / 0

0 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

closed

Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Bryan C. Hanson

Executive Officer, Director · Warsaw, IN

Christopher B. Begley

Director · Warsaw, IN

Betsy J. Bernard

Director · Warsaw, IN

Michael J. Farrell

Director · Warsaw, IN

Robert A. Hagemann

Director · Warsaw, IN

Arthur J. Higgins

Director · Warsaw, IN

Maria Teresa Hilado

Director · Warsaw, IN

Syed A. Jafry

Director · Warsaw, IN

Sreelakshmi A. Kolli

Director · Warsaw, IN

Michael W. Michelson

Director · Warsaw, IN

Rachel W. Ellingson

Executive Officer · Warsaw, IN

Paul A. Stellato

Executive Officer · Warsaw, IN

Chad F. Phipps

Executive Officer · Warsaw, IN

Ivan F. Tornos

Executive Officer · Warsaw, IN

Suketu F. Upadhyay

Executive Officer · Warsaw, IN

Wilfred F. van Zuilen

Executive Officer · Warsaw, IN

Lori F. Winkler

Executive Officer · Warsaw, IN

Sang F. Yi

Executive Officer · Warsaw, IN

Questions About ZIMMER BIOMET HOLDINGS, INC.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is ZIMMER BIOMET HOLDINGS, INC.?

ZIMMER BIOMET HOLDINGS, INC. is a Delaware corporation that filed a Form D with the SEC on February 15, 2023 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of equity.

Is ZIMMER BIOMET HOLDINGS, INC. legit?

AltStreet does not rate legitimacy; it reports the public record. ZIMMER BIOMET HOLDINGS, INC. filed a Form D with the SEC on February 15, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $216,086,331 sold to 157 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is ZIMMER BIOMET HOLDINGS, INC. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that ZIMMER BIOMET HOLDINGS, INC. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has ZIMMER BIOMET HOLDINGS, INC. raised?

ZIMMER BIOMET HOLDINGS, INC. reported $216,086,331 sold from 157 investors of a $216,086,331 total offering as of the Form D filed February 15, 2023.

Who can invest in ZIMMER BIOMET HOLDINGS, INC.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in ZIMMER BIOMET HOLDINGS, INC.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling ZIMMER BIOMET HOLDINGS, INC. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Who is behind ZIMMER BIOMET HOLDINGS, INC.?

The Form D lists 18 related persons: Bryan C. Hanson, executive officer, director; Christopher B. Begley, director; Betsy J. Bernard, director; Michael J. Farrell, director; Robert A. Hagemann, director; Arthur J. Higgins, director; Maria Teresa Hilado, director; Syed A. Jafry, director, and 10 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is ZIMMER BIOMET HOLDINGS, INC. located?

The issuer's address on its SEC filings is 345 East Main Street, Warsaw, IN 46580. Its phone number of record is 5742676131. It is organized under the laws of Delaware.

How long is the ZIMMER BIOMET HOLDINGS, INC. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is ZIMMER BIOMET HOLDINGS, INC.'s revenue?

The Form D reports a revenue range of Over $100,000,000.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.